Date: November 17, 2023
Your Name:Wenjing Peng
Manuscript Title: Novel biomarkers based on dual-energy CT for risk stratification of very early distant metastasis in
colorectal cancer after surgery
Manuscript number (if known): QIMS-23-861

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_√_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_√_None	
ε	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	5 Payment or honoraria for	_✔_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
_			
7	Support for attending meetings and/or travel	_✓_None	
8	Patents planned, issued or	_✓_None	
	pending		
9	Participation on a Data	_✓_None	
	Safety Monitoring Board or		
	Advisory Board		
10		_✓_None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_✓_None	
12	Receipt of equipment,	_√_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	✓ None	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: November 17, 2023 _	
Your Name:Lijuan Wan_	
Manuscript Title: Novel bior	narkers based on dual-energy CT for risk stratification of very early distant metastasis in
colorectal cancer after surgery	
Manuscript number (if known): QIMS-23-861

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial✓_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_√_None	
3	Royalties or licenses	_√_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	✓ None	
0	testimony		
7	Support for attending meetings and/or travel	_✓_None	
8	Patents planned, issued or	_✓_None	
	pending		
9	9 Participation on a Data Safety Monitoring Board or Advisory Board	_√_None	
10	Leadership or fiduciary role	✓ None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Descint of equipment	(Nama	
12	Receipt of equipment, materials, drugs, medical	_√_None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_✓_None	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: November 17, 2023	_
Your Name:Rui Zhao	
Manuscript Title: Novel biomarkers based on dual-energy CT for risk stratification of very early distant metastas	sis in
colorectal cancer after surgery	
Manuscript number (if known): QIMS-23-861	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial✓_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_✔_None	
ε	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	✓ None	
0	testimony		
7	Support for attending meetings and/or travel	_✔_None	
8	Patents planned, issued or	_✓_None	
	pending		
9	9 Participation on a Data Safety Monitoring Board or Advisory Board	_√_None	
10	Leadership or fiduciary role	✓ None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Descint of equipment	(Nama	
12	Receipt of equipment, materials, drugs, medical	_√_None	
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	_✓_None	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:	November 17, 2023
Your Nam	ne: Shuang Chen
Manuscri	pt Title: Novel biomarkers based on dual-energy CT for risk stratification of very early distant metastasis in
colorectal	l cancer after surgery
Manuscri	pt number (if known): QIMS-23-861

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_✔_None	
S	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for	_√_None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	✓ None	
Ŭ	testimony		
	,		
7	Support for attending meetings and/or travel	_✓_None	
8	Patents planned, issued or	_✓_None	
	pending		
0	Deuticiantica en e Dete		
9	Participation on a Data Safety Monitoring Board or	_√_None	
	Advisory Board		
10	•	✓ None	
in other board, society, committee or advocacy			
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	_√_None	

None.

Please place an "X" next to the following statement to indicate your agreement:

Date:	November 17, 2023
Your Nan	ne:Shushan Dong
Manuscri	pt Title: Novel biomarkers based on dual-energy CT for risk stratification of very early distant metastasis in
colorecta	l cancer after surgery
Manuscri	pt number (if known): QIMS-23-861

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_√_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_√_None	
ε	Royalties or licenses	_✔_None	
4	Consulting fees	_✔_None	

5	Payment or honoraria for lectures, presentations,	_√_None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_√_None	
7	Support for attending meetings and/or travel	_✓_None	
8	Patents planned, issued or	✓ None	
	pending		
9	Participation on a Data Safety Monitoring Board or	_√_None	
	Advisory Board		
10	Leadership or fiduciary role	✓ None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_√_None	
12	Receipt of equipment,	None	
12	materials, drugs, medical writing, gifts or other services		
13	Other financial or non- financial interests	Shushan Dong is a current employee of Philips Healthcare.	

Shushan Dong is a current employee of Philips Healthcare.

Please place an "X" next to the following statement to indicate your agreement:

Date: November 17, 2023
Your Name:Lin Li
Manuscript Title: Novel biomarkers based on dual-energy CT for risk stratification of very early distant metastasis in
colorectal cancer after surgery
Manuscript number (if known): QIMS-23-861

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_√_None		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	_√_None		
3	Royalties or licenses	_√_None		
4	Consulting fees	_√_None		

5	lectures, presentations,	_√_None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_√_None	
	testimony		
7	Support for attending meetings and/or travel	_✔_None	
8	Patents planned, issued or	_✓_None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_√_None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	materials, drugs, medical	_√_None	
	writing, gifts or other services		
13	Other financial or non-	_√_None	
15	financial interests		
		-	

None.

Please place an "X" next to the following statement to indicate your agreement:

 Date:
 November 17, 2023

 Your Name:
 Hongmei Zhang

 Manuscript Title:
 Novel biomarkers based on dual-energy CT for risk stratification of very early distant metastasis in colorectal cancer after surgery

 Manuscript number (if known):
 QIMS-23-861

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials,	1. CAMS Innovation Fund for Medical Sciences (CIFMS)	grant number 2021-I2M-C&T-A-017
	medical writing, article processing charges, etc.) No time limit for this item.	2. Capital's Funds for Health Improvement and Research (CFH)	grant number 2022-2-4024
		3. National Natural Science Foundation of China	grant number 81971589
		4. 2020 SKY Imaging Research Fund	grant number Z-2014-07-2003-01
		5. CAMS Innovation Fund for Medical Sciences (CIFMS)	grant number 2022-I2M-C&T-B-077
2	Grants or contracts from	Time frame: past ✓ None	36 months

	I		
	any entity (if not indicated		
2	in item #1 above).		
3	Royalties or licenses	_√_None	
4	Consulting fees		
4	consulting lees	_✓_None	
5	Payment or honoraria for	_√_None	
-	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_✓_None	
	testimony		
7	Support for attending	✓_None	
/	meetings and/or travel		
8	Patents planned, issued or	_√_None	
	pending		
9	Participation on a Data	_√_None	
	Safety Monitoring Board or Advisory Board		
10			
10	Leadership or fiduciary role in other board, society,	_√_None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_√_None	
12	materials, drugs, medical	_√_None	
	writing, gifts or other services		
13	Other financial or non-	_√_None	
	financial interests		

1.Funding: This work was supported by CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2021-12M-C&T-A-017]; Capital's Funds for Health Improvement and Research (CFH) [grant number 2022-2-4024]; the National Natural Science Foundation of China [grant number 81971589]; 2020 SKY Imaging Research Fund [grant number Z-2014-07-2003-01]; and CAMS Innovation Fund for Medical Sciences (CIFMS) [grant number 2022-12M-C&T-B-077]. Please place an "X" next to the following statement to indicate your agreement: